Mechanism of Action
Satellite Cell Activation
The Ec domain peptide of MGF acts on muscle satellite cells (quiescent myogenic stem cells) via a receptor pathway distinct from the classical IGF-1R. MGF's Ec peptide binds to a putative MGF-specific receptor and activates satellite cell proliferation, the essential first step in muscle repair. Without satellite cell activation, new myonuclei cannot be added and hypertrophy is limited. IGF-1 then drives differentiation of these activated satellite cells into mature myoblasts that fuse with existing fibers. The two peptides are thus sequential rather than redundant in the repair cascade.
PEGylation Pharmacokinetics
Native MGF is degraded within 2-30 minutes in circulation by proteases, limiting its utility after systemic injection. PEGylation attaches hydrophilic polyethylene glycol polymers to the peptide, creating steric shielding that dramatically reduces protease accessibility. This extends the terminal half-life to approximately 5-7 days, allowing twice-weekly dosing to maintain sustained receptor stimulation. PEGylation also reduces immunogenicity. The trade-off is increased molecular weight (to ~40 kDa), which may affect tissue penetration compared to native MGF.
Neuroprotective and Cardioprotective Actions
MGF receptors are expressed in cardiac muscle and neuronal tissue. In rodent models, PEG-MGF reduces cardiomyocyte apoptosis following ischemia-reperfusion injury and improves post-MI left ventricular function. Neurological research shows MGF promotes motor neuron survival in ALS models and spinal cord injury models. These extra-muscular actions suggest PEG-MGF has broader repair signaling roles beyond skeletal muscle.
Research Summary
Skeletal Muscle Hypertrophy and Repair
Moderate EvidenceRodent studies demonstrate significant increases in muscle cross-sectional area and fiber number following PEG-MGF administration, particularly when combined with resistance exercise or denervation-reinnervation protocols. Yang and Goldspink's lab at UCL published foundational work showing MGF increases in response to exercise and that exogenous MGF accelerates recovery from muscle damage. Human studies are absent from the published literature; extrapolation from animal data requires caution.
Cardiac and Neurological Models
EmergingIn MI models, PEG-MGF administered post-infarction reduced infarct size, preserved ejection fraction, and decreased apoptotic cardiomyocytes versus controls. ALS model mice showed significantly delayed motor neuron loss and extended survival with PEG-MGF treatment. These findings have generated interest in cardiac and neurological repair applications, though translation to humans has not occurred.
Calculate your PEG-MGF dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Muscle recovery / hypertrophy | 200-400 mcg | Twice weekly | Subcutaneous, post-workout or AM rest day |
| Injury repair | 200 mcg | 2-3x/week | Subcutaneous, proximal to injury site |
| Stack with IGF-1 LR3 | 200 mcg PEG-MGF + 50-100 mcg IGF-1 | PEG-MGF 2x/week; IGF-1 daily | Subcutaneous |
PEG-MGF is WADA-prohibited for competition athletes. The satellite cell activation mechanism is most relevant in the post-damage/post-exercise window, timing around training is physiologically rational. Cycle off to avoid receptor desensitization.
Interactions
Safety Profile
Human safety data for PEG-MGF is essentially absent, no published clinical trials exist. Extrapolation from animal studies suggests it is well-tolerated, with no reported organ toxicity at typical research doses. The primary theoretical concerns relate to its growth-promoting activity: potential for promoting growth in pre-existing neoplasms (via satellite cell activation in tumor stroma) and the theoretical risk of organomegaly with very high doses. PEGylation introduces the question of PEG accumulation in tissues with chronic use, though at the doses and cycle lengths used in research contexts this is unlikely to be clinically significant. WADA-prohibited. Not FDA approved. No human clinical trials registered as of 2025.
References
- [1]Yang SY, Goldspink G. "Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation." FEBS Lett. 2002;522(1-3):156-160.
- [2]Goldspink G. "Research on mechano growth factor: its potential for optimising physical training as well as misuse in doping." Br J Sports Med. 2005;39(11):787-788.
- [3]Stavropoulou A et al. "Cardiac protection from ischemia-reperfusion injury by PEG-MGF." Mol Med. 2012;18(1):1407-1416.